What are the Security Level targets for pharmaceutical manufacturers?
Typical SL targets for pharmaceutical manufacturers are SL 2 to SL 3.
IEC 62443 OT cybersecurity standards services for pharmaceutical manufacturers. The engagement covers the zone-conduit modeling, the Security Level (SL) targets, the SL-T, SL-A, SL-C assessment, the FDA cybersecurity guidance alignment, and the operating routine.
The zone-conduit modeling defines the security zones, the conduits, the Security Level (SL) targets, and the security requirements.
The Security Level assessment covers the SL-T (target), the SL-A (achieved), and the SL-C (capability).
The FDA cybersecurity guidance (2023) for medical devices and the 2024 guidance for pharma require cybersecurity to be considered in the system design, the validation, and the post-market surveillance.
Use this IEC 62443 OT Cybersecurity page as a planning checkpoint before vendor selection, architecture review, validation scoping or implementation sequencing. The strongest next step is to compare the guidance with your current SOPs, system inventory, batch records, data flows and QA review routines so the discussion starts from evidence instead of assumptions.
For IEC 62443 OT Cybersecurity, prepare the records, owners, risks and decision criteria linked to zone-conduit and security levels, sl-t, sl-a, sl-c assessment, fda cybersecurity guidance. Useful evidence includes current process maps, interface lists, audit trail expectations, exception workflows, data retention rules and the business reason for changing the current operating model.
Typical SL targets for pharmaceutical manufacturers are SL 2 to SL 3.
A typical IEC 62443 assessment takes 4-8 weeks.